Pseudomonas aeruginosa: Infections and novel approaches to treatment "Knowing the enemy " the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment

被引:43
|
作者
Sathe, Nikhil [1 ,2 ]
Beech, Peter [2 ]
Croft, Larry [2 ]
Suphioglu, Cenk [3 ]
Kapat, Arnab [1 ]
Athan, Eugene [4 ]
机构
[1] Reliance Life Sci Pvt Ltd, Dhirubhai Ambani Life Sci Ctr, Thane Belapur Rd, Navi Mumbai 400701, India
[2] Deakin Univ, Sch Life & Environm Sci, Melbourne Burwood Campus,221 Burwood Highway, Burwood, Vic 3125, Australia
[3] Deakin Univ, Sch Life & Environm Sci, NeuroAllergy Res Lab, Geelong Campus Waurn Ponds,75 Pigdons Rd, Waurn Ponds, Vic 3216, Australia
[4] Deakin Univ, Sch Med, POB 281, Geelong, 3220, Australia
来源
INFECTIOUS MEDICINE | 2023年 / 2卷 / 03期
关键词
Pseudomonas; Infections; Antibiotics; Resistance; Novel Approaches; Bacteriophages; Immunotherapy; Vaccines; URINARY-TRACT-INFECTION; VENTILATOR-ASSOCIATED PNEUMONIA; QUORUM-SENSING INHIBITORS; SUPPURATIVE OTITIS-MEDIA; CYSTIC-FIBROSIS PATIENTS; MULTIDRUG-RESISTANT; BIOFILM FORMATION; RISK-FACTORS; NOSOCOMIAL INFECTIONS; ANTIMICROBIAL RESISTANCE;
D O I
10.1016/j.imj.2023.05.003
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Pseudomonas aeruginosa is an aerobic Gram-negative rod-shaped bacterium with a comparatively large genome and an impressive genetic capability allowing it to grow in a variety of environments and tolerate a wide range of physical conditions. This biological flexibility enables the P. aeruginosa to cause a broad range of infections in patients with serious underlying medical conditions, and to be a principal cause of health care associated infection worldwide. The clinical manifestations of P. aeruginosa include mostly health care associated infections and community-acquired infections. P. aeruginosa possesses an array of virulence factors that counteract host defence mechanisms. It can directly damage host tissue while utilizing high levels of intrinsic and acquired antimicrobial resistance mechanisms to counter most classes of antibiotics. P. aeruginosa co-regulates multiple resistance mechanisms by perpetually moving targets poses a significant therapeutic challenge. Thus, there is an urgent need for novel approaches in the development of anti- Pseudomonas agents. Here we review the principal infections caused by P. aeruginosa and we discuss novel therapeutic options to tackle antibiotic resistance and treatment of P. aeruginosa infections that may be further developed for clinical practice.
引用
收藏
页码:178 / 194
页数:17
相关论文
共 50 条
  • [21] Novel therapeutic strategies to counter Pseudomonas aeruginosa infections
    Fothergill, Joanne L.
    Winstanley, Craig
    James, Chloe E.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2012, 10 (02) : 219 - 235
  • [22] Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections
    Escola-Verge, Laura
    Pigrau, Carles
    Los-Arcos, Ibai
    Arevalo, Angel
    Vinado, Belen
    Campany, David
    Larrosa, Nieves
    Nuvials, Xavier
    Ferrer, Ricard
    Len, Oscar
    Almirante, Benito
    INFECTION, 2018, 46 (04) : 461 - 468
  • [23] USE OF CIPROFLOXACIN IN THE TREATMENT OF PSEUDOMONAS-AERUGINOSA INFECTIONS
    FOLLATH, F
    BINDSCHEDLER, M
    WENK, M
    FREI, R
    STALDER, H
    REBER, H
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1986, 5 (02) : 236 - 240
  • [24] ANTIBIOTIC-TREATMENT OF PSEUDOMONAS-AERUGINOSA INFECTIONS
    MODAI, J
    THABAUT, A
    PRESSE MEDICALE, 1986, 15 (30): : 1417 - 1420
  • [25] Bacteriophages in the Experimental Treatment of Pseudomonas aeruginosa Infections in Mice
    Saussereau, Emilie
    Debarbieux, Laurent
    ADVANCES IN VIRUS RESEARCH, VOL 83: BACTERIOPHAGES, PT B, 2012, 83 : 123 - 141
  • [26] PSEUDOMONAS AERUGINOSA INFECTIONS AND THEIR TREATMENT - A REPORT OF 33 CASES
    VILLEDIE.R
    ALPERINE, G
    ABBATUCC.JS
    PRESSE MEDICALE, 1970, 78 (44): : 1933 - &
  • [27] Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections
    Laura Escolà-Vergé
    Carles Pigrau
    Ibai Los-Arcos
    Ángel Arévalo
    Belen Viñado
    David Campany
    Nieves Larrosa
    Xavier Nuvials
    Ricard Ferrer
    Oscar Len
    Benito Almirante
    Infection, 2018, 46 : 461 - 468
  • [28] The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update
    Dan Reynolds
    Marin Kollef
    Drugs, 2021, 81 : 2117 - 2131
  • [29] The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update
    Reynolds, Dan
    Kollef, Marin
    DRUGS, 2021, 81 (18) : 2117 - 2131
  • [30] CEFSULODIN TREATMENT FOR SERIOUS PSEUDOMONAS-AERUGINOSA INFECTIONS
    ROUTMAN, A
    VANMANEN, W
    HADDAD, R
    POLLOCK, B
    HOLMES, B
    MOGABGAB, WJ
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1986, 14 (05) : 242 - 253